Abstract

To evaluate factors affecting peripheral blood hematopoietic stem cell yield in patients undergoing large-volume leukapheresis for autologous peripheral blood stem cell collection. Data from 304 consecutive autologous peripheral blood stem cell donors mobilized with hematopoietic growth factor (usually G-CSF), associated or not with chemotherapy, at Hospital Israelita Albert Einstein between February 1999 and June 2010 were retrospectively analyzed. The objective was to obtain at least 2 × 106 CD34+ cells/kg of body weight. Pre-mobilization factors analyzed included patient's age, gender and diagnosis. Post mobilization parameters evaluated were pre-apheresis peripheral white blood cell count, immature circulating cell count, mononuclear cell count, peripheral blood CD34+ cell count, platelet count, and hemoglobin level. The effect of pre and post-mobilization factors on hematopoietic stem cell collection yield was investigated using logistic regression analysis (univariate and multivariate approaches). Pre-mobilization factors correlating to poor CD34 + cell yield in univariate analysis were acute myeloid leukemia (p = 0.017) and other hematological diseases (p = 0.023). Significant post-mobilization factors included peripheral blood immature circulating cells (p = 0.001), granulocytes (p = 0.002), hemoglobin level (p = 0.016), and CD34+ cell concentration (p < 0.001) in the first harvesting day. However, according to multivariate analysis, peripheral blood CD34+ cell content (p < 0.001) was the only independent factor that significantly correlated to poor hematopoietic stem cell yield. In this study, peripheral blood CD34+ cell concentration was the only factor significantly correlated to yield in patients submitted to for autologous collection.

Highlights

  • High-dose chemotherapy, together with hematopoietic stem cell (HSC) harvest, has been successfully used in the management of a variety of malignant and nonmalignant diseases[1]

  • Autologous peripheral blood stem cells (PBSC) are usually collected by leukapheresis during hematologic recovery phase from the administration of the mobilizing agents

  • Data from 304 consecutive autologous PBSC donors mobilized with granulocyte colony-stimulating factor (G-CSF) associated or not with chemotherapy at Hospital Israelita Albert Einstein (HIAE) between February 1999 and June 2010 were retrospectively analyzed

Read more

Summary

INTRODUCTION

High-dose chemotherapy, together with hematopoietic stem cell (HSC) harvest, has been successfully used in the management of a variety of malignant and nonmalignant diseases[1]. Autologous PBSC are usually collected by leukapheresis during hematologic recovery phase from the administration of the mobilizing agents. LVL was reported as a safe and useful strategy to maximize autologous CD34+ cell yield especially in patients with low PB CD34+ cell concentration[13,14,15,16,17,18]. From 5 to 40% of patients undergoing autologous PBSC collection failed to achieve the minimum dose of 2 x 106 CD34+ cell/ kg body weight considering a single mobilization attempt. There is still no specific factor to identify a poor mobilizer(7,19.20)

METHODS
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call